16,303 Shares in Enliven Therapeutics, Inc. $ELVN Bought by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL bought a new stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN) during the third quarter, HoldingsChannel reports. The fund bought 16,303 shares of the company’s stock, valued at approximately $334,000.

A number of other large investors have also added to or reduced their stakes in the company. Commodore Capital LP lifted its stake in Enliven Therapeutics by 0.4% during the second quarter. Commodore Capital LP now owns 4,692,809 shares of the company’s stock worth $94,138,000 after purchasing an additional 17,809 shares during the last quarter. Polar Capital Holdings Plc lifted its position in Enliven Therapeutics by 1.5% in the 3rd quarter. Polar Capital Holdings Plc now owns 3,095,007 shares of the company’s stock worth $63,355,000 after buying an additional 44,713 shares during the last quarter. Vanguard Group Inc. lifted its position in Enliven Therapeutics by 5.9% in the 3rd quarter. Vanguard Group Inc. now owns 2,553,014 shares of the company’s stock worth $52,260,000 after buying an additional 142,378 shares during the last quarter. Vestal Point Capital LP boosted its stake in Enliven Therapeutics by 364.0% in the third quarter. Vestal Point Capital LP now owns 1,160,000 shares of the company’s stock worth $23,745,000 after buying an additional 910,000 shares in the last quarter. Finally, Duquesne Family Office LLC boosted its stake in Enliven Therapeutics by 104.6% in the third quarter. Duquesne Family Office LLC now owns 947,405 shares of the company’s stock worth $19,393,000 after buying an additional 484,405 shares in the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on ELVN shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, January 21st. Mizuho lifted their target price on shares of Enliven Therapeutics from $41.00 to $45.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 25th. Wall Street Zen downgraded shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Finally, HC Wainwright upped their price target on shares of Enliven Therapeutics from $48.00 to $56.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $43.40.

Insider Buying and Selling

In other news, Director Richard A. Heyman sold 1,230 shares of the firm’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $26.18, for a total transaction of $32,201.40. Following the completion of the transaction, the director directly owned 22,647 shares in the company, valued at $592,898.46. This trade represents a 5.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Joseph P. Lyssikatos sold 5,000 shares of the stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $29.04, for a total transaction of $145,200.00. Following the sale, the insider directly owned 740,188 shares in the company, valued at $21,495,059.52. This trade represents a 0.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 232,180 shares of company stock valued at $6,217,033. 25.90% of the stock is owned by company insiders.

Enliven Therapeutics Stock Performance

Shares of Enliven Therapeutics stock opened at $37.79 on Thursday. Enliven Therapeutics, Inc. has a 52-week low of $13.30 and a 52-week high of $40.62. The stock has a market capitalization of $2.26 billion, a price-to-earnings ratio of -20.32 and a beta of 0.33. The company’s 50 day moving average price is $29.22 and its 200-day moving average price is $23.37.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.06). As a group, equities research analysts forecast that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.